SRPT Valuation

Sarepta Therapeutics Inc

Add to Watchlist

Advanced Chart

16.750

+0.92(5.812%)1D

Overview
Forecast
Valuation
Earnings

SRPT Relative Valuation

SRPT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SRPT is overvalued; if below, it's undervalued.

Historical Valuation

Sarepta Therapeutics Inc (SRPT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.00 is considered Undervalued compared with the five-year average of -0.02. The fair price of Sarepta Therapeutics Inc (SRPT) is between 1117.92 to 1226.54 according to relative valuation methord. Compared to the current price of 16.75 USD , Sarepta Therapeutics Inc is Undervalued By 98.5%.

Relative Value

Fair Zone

1117.92-1226.54

Current Price：16.75

98.5%

Undervalued

0.00

Trailing

Forward

-9.19

EV/EBITDA

Sarepta Therapeutics Inc. (SRPT) has a current EV/EBITDA of -9.19. The 5-year average EV/EBITDA is -0.70. The thresholds are as follows: Strongly Undervalued below -171.25, Undervalued between -171.25 and -85.98, Fairly Valued between 84.58 and -85.98, Overvalued between 84.58 and 169.86, and Strongly Overvalued above 169.86. The current Forward EV/EBITDA of -9.19 falls within the Historic Trend Line -Fairly Valued range.

-14.46

EV/EBIT

Sarepta Therapeutics Inc. (SRPT) has a current EV/EBIT of -14.46. The 5-year average EV/EBIT is 3.32. The thresholds are as follows: Strongly Undervalued below -76.64, Undervalued between -76.64 and -36.66, Fairly Valued between 43.30 and -36.66, Overvalued between 43.30 and 83.28, and Strongly Overvalued above 83.28. The current Forward EV/EBIT of -14.46 falls within the Historic Trend Line -Fairly Valued range.

1.00

Sarepta Therapeutics Inc. (SRPT) has a current PS of 1.00. The 5-year average PS is 7.97. The thresholds are as follows: Strongly Undervalued below -0.10, Undervalued between -0.10 and 3.93, Fairly Valued between 12.00 and 3.93, Overvalued between 12.00 and 16.04, and Strongly Overvalued above 16.04. The current Forward PS of 1.00 falls within the Undervalued range.

2.65

P/OCF

Sarepta Therapeutics Inc. (SRPT) has a current P/OCF of 2.65. The 5-year average P/OCF is -6.13. The thresholds are as follows: Strongly Undervalued below -364.87, Undervalued between -364.87 and -185.50, Fairly Valued between 173.24 and -185.50, Overvalued between 173.24 and 352.61, and Strongly Overvalued above 352.61. The current Forward P/OCF of 2.65 falls within the Historic Trend Line -Fairly Valued range.

-4.91

P/FCF

Sarepta Therapeutics Inc. (SRPT) has a current P/FCF of -4.91. The 5-year average P/FCF is -32.25. The thresholds are as follows: Strongly Undervalued below -146.67, Undervalued between -146.67 and -89.46, Fairly Valued between 24.96 and -89.46, Overvalued between 24.96 and 82.16, and Strongly Overvalued above 82.16. The current Forward P/FCF of -4.91 falls within the Historic Trend Line -Fairly Valued range.

Sarepta Therapeutics Inc (SRPT) has a current Price-to-Book (P/B) ratio of 1.37. Compared to its 3-year average P/B ratio of 13.82 , the current P/B ratio is approximately -90.08% higher. Relative to its 5-year average P/B ratio of 12.63, the current P/B ratio is about -89.14% higher. Sarepta Therapeutics Inc (SRPT) has a Forward Free Cash Flow (FCF) yield of approximately -44.69%. Compared to its 3-year average FCF yield of -6.30%, the current FCF yield is approximately 609.28% lower. Relative to its 5-year average FCF yield of -6.18% , the current FCF yield is about 622.95% lower.

1.37

P/B

Median3y

13.82

Median5y

12.63

-44.69

FCF Yield

Median3y

-6.30

Median5y

-6.18

Competitors Valuation Multiple

The average P/S ratio for SRPT's competitors is 276.00, providing a benchmark for relative valuation. Sarepta Therapeutics Inc Corp (SRPT) exhibits a P/S ratio of 1.00, which is -99.64% above the industry average. Given its robust revenue growth of 80.15%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

SRPT.O

Sarepta Therapeutics Inc

Phibro Animal Health Corp

Praxis Precision Medicines Inc

Spyre Therapeutics Inc

Loss

1.04B

Performance Decomposition

Market capitalization of SRPT decreased by 88.22% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -0.86 to -6.16.

The secondary factor is the Revenue Growth, contributed 80.15%to the performance.

Overall, the performance of SRPT in the past 1 year is driven by P/E Change. Which is more unsustainable.

80.15%

413.46M → 744.86M

Revenue Growth

-787.41%

8.74 → -60.08

Margin Expansion

619.04%

-0.86 → -6.16

P/E Change

-88.22%